Barrow Hanley Mewhinney & Strauss LLC Has $371.24 Million Stake in Sanofi (NASDAQ:SNY)

Barrow Hanley Mewhinney & Strauss LLC trimmed its position in Sanofi (NASDAQ:SNY - Free Report) by 1.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,697,289 shares of the company's stock after selling 140,540 shares during the period. Sanofi makes up approximately 1.3% of Barrow Hanley Mewhinney & Strauss LLC's holdings, making the stock its 29th biggest holding. Barrow Hanley Mewhinney & Strauss LLC owned 0.30% of Sanofi worth $371,240,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Abel Hall LLC grew its stake in Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company's stock valued at $530,000 after acquiring an additional 194 shares during the period. Providence Capital Advisors LLC grew its position in shares of Sanofi by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock valued at $2,653,000 after purchasing an additional 201 shares during the period. Keudell Morrison Wealth Management increased its stake in Sanofi by 1.7% during the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock worth $624,000 after purchasing an additional 217 shares in the last quarter. Bailard Inc. increased its stake in Sanofi by 1.4% during the 4th quarter. Bailard Inc. now owns 16,359 shares of the company's stock worth $789,000 after purchasing an additional 220 shares in the last quarter. Finally, Bessemer Group Inc. raised its holdings in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after buying an additional 242 shares during the period. Institutional investors own 14.04% of the company's stock.

Analysts Set New Price Targets

SNY has been the topic of a number of research analyst reports. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. BNP Paribas initiated coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price on the stock. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target for the company. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $63.33.

Sanofi Stock Performance

SNY stock traded down $0.19 during trading hours on Wednesday, reaching $52.21. The stock had a trading volume of 1,900,937 shares, compared to its average volume of 2,375,080. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock has a 50-day simple moving average of $52.54 and a 200 day simple moving average of $51.90. The stock has a market capitalization of $131.88 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sanofi's quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter last year, the company posted $1.78 earnings per share. Analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is currently 57.14%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.